Literature DB >> 1583408

In vivo catabolism of human kallikrein-binding protein and its complex with tissue kallikrein.

W Xiong1, C Q Tang, G X Zhou, L Chao, J Chao.   

Abstract

We recently identified and purified a novel human kallikrein-binding protein (HKBP) from human plasma. The HKBP forms a 92 kd sodium dodecyl sulfate-stable and heat-stable complex with tissue kallikrein. This study was undertaken to characterize the plasma clearance and tissue distribution of exogenously administered HKBP and its complex with tissue kallikrein. Human tissue kallikrein was first incubated with purified HKBP, and the high-molecular-weight complex was separated from unbound proteins on a high-pressure liquid chromatography gel filtration column. Tissue kallikrein, kallikrein-binding protein, and their complex were labeled with iodine-125 and then injected intravenously into Sprague-Dawley rats. The disappearance rates of trichloracetic acid-precipitable radioactivity from the circulation were determined. The clearance profile of HKBP shows a nonlinear pattern with an apparent half-life of 65 minutes (n = 4). The plasma clearance of HKBP complexed with kallikrein shows a similar profile but a shorter half-life of 33 minutes (n = 3). HKBP and its complex with kallikrein were mainly taken up by the liver but to a lesser degree by the kidney, lung, and other tissues. Labeled human kallikrein has an apparent half-life of 8 minutes (n = 4), and its clearance consists of a fast and a slow component. The data indicate that kallikrein-HKBP complex is cleared from the circulation two times faster than that of the binding protein alone and that it persists in the circulation four times longer than kallikrein alone. The results support the notion that more than one pathway exists for the metabolism of tissue kallikrein and that HKBP plays a role in modulating tissue kallikrein's bioavailability.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1583408

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  8 in total

Review 1.  Protective Role of Kallistatin in Vascular and Organ Injury.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

2.  Kallistatin is a potent new vasodilator.

Authors:  J Chao; J N Stallone; Y M Liang; L M Chen; D Z Wang; L Chao
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

Review 3.  Kallistatin suppresses cancer development by multi-factorial actions.

Authors:  Julie Chao; Pengfei Li; Lee Chao
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-14       Impact factor: 6.312

4.  Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection.

Authors:  Shiou-Ling Lu; Chiau-Yuang Tsai; Yueh-Hsia Luo; Chih-Feng Kuo; Wei-Chieh Lin; Yu-Tzu Chang; Jiunn-Jong Wu; Woei-Jer Chuang; Ching-Chuan Liu; Lee Chao; Julie Chao; Yee-Shin Lin
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

5.  Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement.

Authors:  A Del Rosso; O Distler; A F Milia; C Emanueli; L Ibba-Manneschi; S Guiducci; M L Conforti; S Generini; A Pignone; S Gay; P Madeddu; M Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

6.  Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease.

Authors:  Antoni Stadnicki; Urszula Mazurek; Maciej Gonciarz; Danuta Plewka; Grazyna Nowaczyk; Joanna Orchel; Ezbieta Pastucha; Andrzej Plewka; Tadcusz Wilczok; Robert W Colman
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

7.  Elevated circulation levels of an antiangiogenic SERPIN in patients with diabetic microvascular complications impair wound healing through suppression of Wnt signaling.

Authors:  Jeffrey D McBride; Alicia J Jenkins; Xiaochen Liu; Bin Zhang; Kyungwon Lee; William L Berry; Ralf Janknecht; Courtney T Griffin; Christopher E Aston; Timothy J Lyons; James J Tomasek; Jian-Xing Ma
Journal:  J Invest Dermatol       Date:  2014-01-24       Impact factor: 8.551

8.  Proteomic analysis of serum biomarkers for prediabetes using the Long-Evans Agouti rat, a spontaneous animal model of type 2 diabetes mellitus.

Authors:  Eri Takahashi; Hiroyuki Unoki-Kubota; Yukiko Shimizu; Tadashi Okamura; Wakiko Iwata; Hiroshi Kajio; Ritsuko Yamamoto-Honda; Tomoko Shiga; Shigeo Yamashita; Kazuyuki Tobe; Akinori Okumura; Michihiro Matsumoto; Kazuki Yasuda; Mitsuhiko Noda; Yasushi Kaburagi
Journal:  J Diabetes Investig       Date:  2017-03-27       Impact factor: 4.232

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.